01—Abstract
Summary
Summary of the 8-K filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Viatris Inc. filed a Form 8-K reporting that on August 4, 2025, its Board of Directors increased the number of directors from 14 to 15 and appointed David Simmons as an independent director, effective immediately, with a term expiring at the Company's 2025 annual meeting of shareholders.
The Board anticipates naming Mr. Simmons to one or more committees but has not yet determined which committees; the Company says it will file an amendment to this Form 8-K once those are determined. Mr. Simmons will receive compensation consistent with the Company's other non-employee directors, and the Company has entered into an indemnification agreement with him. The filing states there are no arrangements or understandings between Mr. Simmons and any other persons regarding his selection, and he has no material interest in any related-person transaction requiring disclosure under Item 404(a) of Regulation S-K.
The accompanying press release (Exhibit 99.1), dated August 5, 2025, describes Mr. Simmons as CEO of Caliber Holdings Corporation and a former Operating Partner of Hellman & Friedman, LLC, Chairman and CEO of PPD, Inc., and a 15-plus-year veteran of Pfizer Inc., where he led the Established Products Unit. Viatris Chair Melina Higgins and CEO Scott A.
Smith both commented on his appointment, with Higgins citing his pharmaceutical industry, drug development and capital markets knowledge and his familiarity with the Company's established products portfolio. The filing is a board-composition change and does not report financial results or guidance.
02—Key points
Key Highlights
- Board expanded from 14 to 15 directors with the appointment of David Simmons, effective immediately (August 4, 2025).
- Mr. Simmons is designated an independent director under NASDAQ listing rules.
- His initial term expires at the Company's 2025 annual meeting of shareholders.
- Committee assignments have not yet been determined; the Company will file an amendment to this 8-K once they are.
- Compensation will be consistent with other non-employee directors, and he has entered into a standard indemnification agreement with the Company.
- Simmons previously led Pfizer's Established Products Unit, the division Chair Melina Higgins cited as relevant to Viatris' portfolio.
- The filing discloses no related-person transactions or arrangements tied to his appointment.
03—Questions
Frequently Asked Questions
Who was appointed to the Viatris Board of Directors?
David Simmons was appointed as an independent member of the Board by action taken on August 4, 2025, effective immediately.
What is his background?
The press release states he is CEO of Caliber Holdings Corporation and previously served as Operating Partner of Hellman & Friedman, LLC, as Chairman and CEO of PPD, Inc., and for more than 15 years at Pfizer Inc., where he became the first President and General Manager of its Established Products Unit. He also currently serves on the board of Cordis.
How long will Mr. Simmons serve on the Board?
His term expires at the Company's 2025 annual meeting of shareholders.
Has Mr. Simmons been assigned to any Board committees?
Not yet. The Board anticipates naming him to one or more committees but has not determined which ones, and the Company will file an amendment to this 8-K once they are determined.
Does the appointment involve any related-party transactions or special arrangements?
The filing states there are no arrangements or understandings between Mr. Simmons and any other person regarding his selection, and he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.
04—Continue